Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma
Lymphangiogenesis, an integral contributor to lymphatic metastasis, is a significant reason for the poor prognosis of cancer patients. Anti-lymphangiogenesis treatment is a promising novel therapeutic direction, especially for tumors resistant to conventional therapies. We confirmed the ectopic expr...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Analytical Cellular Pathology |
| Online Access: | http://dx.doi.org/10.1155/2024/2090450 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558440190312448 |
|---|---|
| author | Juan Peng Dan Liu Hong-feng Zhang Qi-hao Hu Wen Chen Juan Zou Juan Zhang Hui Li An-bo Gao Yu-kun Li |
| author_facet | Juan Peng Dan Liu Hong-feng Zhang Qi-hao Hu Wen Chen Juan Zou Juan Zhang Hui Li An-bo Gao Yu-kun Li |
| author_sort | Juan Peng |
| collection | DOAJ |
| description | Lymphangiogenesis, an integral contributor to lymphatic metastasis, is a significant reason for the poor prognosis of cancer patients. Anti-lymphangiogenesis treatment is a promising novel therapeutic direction, especially for tumors resistant to conventional therapies. We confirmed the ectopic expression of lymphangiogenesis-related genes (LRGs) in lung adenocarcinoma (LUAD) cohorts based on the TCGA database. We constructed a prediction signature with 15 LRG prognostic signatures (F2RL1, LOXL2, MKI67, PTPRM, GPI, POSTN, INHA, LDHA, LINC00857, ITGA2, PECAM1, SOD3, GDF15, SIX1, and FGD5), and the overall survival (OS) was significantly different between the high- and low-risk groups (TCGA-training: p<0.001, TCGA-test: p=0.02, GSE30219: p<0.001, GSE37745: p=0.002, and GSE50081: p=0.002). Moreover, the risk score was also associated with the PIK3CA and BRCA1 pathways. In the nomogram, the prognostic prediction of the risk score was better than that of clinicopathologic parameters in OS, including age, sex, stage, T stage, N stage, and M stage. In summary, we constructed and validated a 15-LRG signature, which may help predict the prognosis of LUAD and offer a possible direction for future research on downstream molecular mechanisms. |
| format | Article |
| id | doaj-art-2f46e1a35c1d45fc987ebacc099095ee |
| institution | Kabale University |
| issn | 2210-7185 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Analytical Cellular Pathology |
| spelling | doaj-art-2f46e1a35c1d45fc987ebacc099095ee2025-02-03T01:32:20ZengWileyAnalytical Cellular Pathology2210-71852024-01-01202410.1155/2024/2090450Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung AdenocarcinomaJuan Peng0Dan Liu1Hong-feng Zhang2Qi-hao Hu3Wen Chen4Juan Zou5Juan Zhang6Hui Li7An-bo Gao8Yu-kun Li9Department of Assisted Reproductive CentreDepartment of Assisted Reproductive CentreDepartment of Laboratory MedicineDepartment of Thoracic SurgeryDepartment of Respiratory and Critical Care MedicineHunan Province Key Laboratory of Tumor Cellular and Molecular PathologyDepartment of Assisted Reproductive CentreDepartment of Assisted Reproductive CentreDepartment of Assisted Reproductive CentreDepartment of Assisted Reproductive CentreLymphangiogenesis, an integral contributor to lymphatic metastasis, is a significant reason for the poor prognosis of cancer patients. Anti-lymphangiogenesis treatment is a promising novel therapeutic direction, especially for tumors resistant to conventional therapies. We confirmed the ectopic expression of lymphangiogenesis-related genes (LRGs) in lung adenocarcinoma (LUAD) cohorts based on the TCGA database. We constructed a prediction signature with 15 LRG prognostic signatures (F2RL1, LOXL2, MKI67, PTPRM, GPI, POSTN, INHA, LDHA, LINC00857, ITGA2, PECAM1, SOD3, GDF15, SIX1, and FGD5), and the overall survival (OS) was significantly different between the high- and low-risk groups (TCGA-training: p<0.001, TCGA-test: p=0.02, GSE30219: p<0.001, GSE37745: p=0.002, and GSE50081: p=0.002). Moreover, the risk score was also associated with the PIK3CA and BRCA1 pathways. In the nomogram, the prognostic prediction of the risk score was better than that of clinicopathologic parameters in OS, including age, sex, stage, T stage, N stage, and M stage. In summary, we constructed and validated a 15-LRG signature, which may help predict the prognosis of LUAD and offer a possible direction for future research on downstream molecular mechanisms.http://dx.doi.org/10.1155/2024/2090450 |
| spellingShingle | Juan Peng Dan Liu Hong-feng Zhang Qi-hao Hu Wen Chen Juan Zou Juan Zhang Hui Li An-bo Gao Yu-kun Li Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma Analytical Cellular Pathology |
| title | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma |
| title_full | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma |
| title_fullStr | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma |
| title_full_unstemmed | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma |
| title_short | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma |
| title_sort | identification of a novel prognostic lymphangiogenesis related signature associated with tumor immunity for guiding therapy in lung adenocarcinoma |
| url | http://dx.doi.org/10.1155/2024/2090450 |
| work_keys_str_mv | AT juanpeng identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT danliu identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT hongfengzhang identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT qihaohu identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT wenchen identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT juanzou identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT juanzhang identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT huili identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT anbogao identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma AT yukunli identificationofanovelprognosticlymphangiogenesisrelatedsignatureassociatedwithtumorimmunityforguidingtherapyinlungadenocarcinoma |